[
  {
    "id": "hct-1",
    "name": "MyRisk Hereditary Cancer Test",
    "vendor": "Myriad Genetics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood (EDTA) or saliva (Oragene kit)",
    "sampleVolume": "3-5 mL blood or 2 mL saliva",
    "method": "NGS with deletion/duplication analysis; includes RiskScore (polygenic risk) for breast cancer",
    "methodCitations": "https://myriad.com/genetic-tests/myrisk-hereditary-cancer/technical-specifications/",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 63,
    "genesAnalyzedCitations": "https://myriad.com/genetic-tests/myrisk-hereditary-cancer/genes-background/",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "EPCAM",
      "APC",
      "MUTYH",
      "TP53",
      "PTEN",
      "PALB2",
      "CHEK2",
      "ATM"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "Cowden",
      "FAP",
      "MUTYH-Associated Polyposis"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Colorectal",
      "Endometrial",
      "Pancreatic",
      "Prostate",
      "Gastric",
      "Melanoma"
    ],
    "analyticalSensitivity": 99.9,
    "analyticalSensitivityNotes": ">99% for sequencing and large rearrangements; Sanger confirmation of variants",
    "analyticalSpecificity": 99.9,
    "vusRateNotes": "Myriad claims lowest VUS rates in industry due to 25+ years of data and largest hereditary cancer database",
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified, CAP Accredited",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Commercial, Medicare, Medicaid; 97% of private insurance covers hereditary cancer testing",
    "selfPayPrice": 249,
    "selfPayPriceCitations": "https://myriad.com/patients-families/myrisk-testing-options/",
    "financialAssistance": "Myriad Financial Assistance Program; free cascade testing for relatives within 90 days",
    "cptCodes": "81162, 81211, 81213, 81214",
    "tat": "14 days",
    "tatCitations": "https://myriad.com/genetic-tests/myrisk-hereditary-cancer/",
    "availableRegions": [
      "US",
      "International"
    ],
    "reportIncludes": [
      "Variant classification",
      "RiskScore (Polygenic)",
      "Management guidelines",
      "Family letter"
    ],
    "geneticCounselingIncluded": "Optional (free post-test with Myriad GC)",
    "cascadeTestingOffered": "Yes - free for blood relatives within 90 days",
    "variantReclassificationPolicy": true,
    "numPublications": 1000,
    "numPublicationsNotes": "Extensive publication history; Myriad's hereditary cancer database is the largest in the industry",
    "uniqueFeatures": "Integrates Polygenic Risk Score (PRS) for breast cancer; RiskScore provides precise risk for women who test negative for mutations; largest hereditary cancer database",
    "limitations": "Panel size (63 genes) smaller than some competitors (80+)",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-2",
    "name": "Invitae Multi-Cancer Panel",
    "vendor": "Invitae (Labcorp)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood or saliva",
    "sampleVolume": "4 mL blood or 2 mL saliva",
    "method": "NGS with deletion/duplication analysis",
    "methodCitations": "https://www.invitae.com/en/providers/test-catalog/test/01101",
    "sequencingPlatform": "Illumina NovaSeq",
    "genesAnalyzed": 84,
    "genesAnalyzedCitations": "https://www.invitae.com/en/providers/test-catalog/test/01101",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "EPCAM",
      "APC",
      "TP53",
      "PTEN",
      "STK11",
      "CDH1"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "Cowden",
      "Peutz-Jeghers",
      "Hereditary Diffuse Gastric Cancer"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Uterine",
      "Colorectal",
      "Gastric",
      "Pancreatic",
      "Prostate",
      "Melanoma",
      "Thyroid",
      "Kidney",
      "Brain",
      "Sarcoma"
    ],
    "analyticalSensitivity": 99.5,
    "analyticalSpecificity": 99.9,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified, CAP Accredited",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Commercial, Medicare",
    "listPrice": 250,
    "selfPayPrice": 250,
    "selfPayPriceCitations": "https://www.invitae.com/en/billing/payment-options",
    "financialAssistance": "Invitae Patient Assistance Program; free family testing for 90 days",
    "cptCodes": "81432, 81433",
    "tat": "10-21 days",
    "availableRegions": [
      "US",
      "International"
    ],
    "reportIncludes": [
      "Variant classification",
      "Management guidelines"
    ],
    "geneticCounselingIncluded": "Yes - includes post-test counseling",
    "cascadeTestingOffered": "Yes - free for 90 days",
    "variantReclassificationPolicy": true,
    "pediatricTesting": true,
    "uniqueFeatures": "Add-on genes available; re-requisition policy allows adding genes later",
    "limitations": "Brand in transition post-acquisition by Labcorp (completed late 2024); operational backend transitioning",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-3",
    "name": "CancerNext-Expanded",
    "vendor": "Ambry Genetics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood or saliva",
    "sampleVolume": "3-7 mL blood or 2 mL saliva",
    "method": "NGS (sequencing and deletion/duplication)",
    "methodCitations": "https://blog.ambrygen.com/ambry/post/361/2024-hereditary-cancer-testing-menu-update",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 90,
    "genesAnalyzedCitations": "https://blog.ambrygen.com/ambry/post/361/2024-hereditary-cancer-testing-menu-update",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "PALB2",
      "ATM",
      "CHEK2",
      "NBN",
      "BARD1"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "Cowden",
      "FAP",
      "PHTS",
      "VHL"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Colorectal",
      "Uterine",
      "Pancreatic",
      "Prostate",
      "Renal",
      "Thyroid",
      "Paraganglioma"
    ],
    "analyticalSensitivity": 99,
    "analyticalSpecificity": 99.9,
    "vusRateNotes": "Ambry known for rigorous variant classification and data sharing to reduce VUS",
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified, CAP Accredited",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Insurance/Medicare",
    "financialAssistance": "Patient Assistance Program available",
    "cptCodes": "81432, 81433",
    "tat": "14-21 days",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Variant classification",
      "Management guidelines"
    ],
    "geneticCounselingIncluded": "No - relies on provider GC",
    "cascadeTestingOffered": "Yes - Family Testing Program",
    "variantReclassificationPolicy": true,
    "numPublications": 50,
    "numPublicationsCitations": "https://pubmed.ncbi.nlm.nih.gov/24763289/",
    "numPublicationsNotes": "LaDuca et al. 2014 (PMID: 24763289) and extensive follow-up publications",
    "uniqueFeatures": "+RNAinsight available (paired RNA/DNA testing) to improve VUS resolution; updated to 90 genes per 2024 menu update",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-4",
    "name": "Empower Hereditary Cancer Test",
    "vendor": "Natera",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood or saliva kit",
    "sampleVolume": "10 mL blood or saliva kit",
    "method": "NGS with deletion/duplication",
    "methodCitations": "https://www.natera.com/oncology/empower-hereditary-cancer-test/",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 81,
    "genesAnalyzedCitations": "https://www.natera.com/oncology/empower-hereditary-cancer-test/",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "EPCAM",
      "TP53",
      "PTEN"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Uterine",
      "Colorectal",
      "Gastric",
      "Pancreatic",
      "Prostate",
      "Melanoma"
    ],
    "analyticalSensitivity": 99,
    "analyticalSpecificity": 99.9,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Insurance/Medicare",
    "selfPayPrice": 249,
    "selfPayPriceCitations": "https://www.natera.com/billing/",
    "financialAssistance": "Compassionate Care Program",
    "tat": "2-3 weeks",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Variant classification",
      "Management guidelines"
    ],
    "geneticCounselingIncluded": "Yes - pre- and post-test sessions available",
    "cascadeTestingOffered": "Yes",
    "variantReclassificationPolicy": true,
    "uniqueFeatures": "Often bundled with Natera's Signatera (MRD) test for cancer patients; 81 genes covers all NCCN-guideline genes",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-5",
    "name": "Color Hereditary Cancer Test",
    "vendor": "Color Health",
    "productType": "Central Lab Service",
    "sampleCategory": "Saliva",
    "sampleType": "Saliva collection kit",
    "sampleVolume": "2 mL saliva",
    "method": "NGS",
    "methodCitations": "https://www.color.com/learn/genes-tested-hereditary-cancer",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 30,
    "genesAnalyzedCitations": "https://www.color.com/learn/genes-tested-hereditary-cancer",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "EPCAM",
      "APC",
      "CHEK2",
      "ATM",
      "PALB2",
      "PTEN",
      "TP53"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "FAP",
      "MAP",
      "Cowden",
      "Peutz-Jeghers"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Uterine",
      "Colorectal",
      "Melanoma",
      "Pancreatic",
      "Prostate",
      "Stomach"
    ],
    "analyticalSensitivity": 99,
    "analyticalSpecificity": 99,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified, CAP Accredited",
    "nyApproved": true,
    "reimbursement": "Self-Pay / Employer",
    "reimbursementNotes": "Largely pivoted to enterprise/employer health programs",
    "listPrice": 250,
    "selfPayPrice": 250,
    "financialAssistance": "Family Testing Program - reduced cost for family members",
    "tat": "3-5 weeks",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Variant classification",
      "Risk information"
    ],
    "geneticCounselingIncluded": "Yes - included in cost",
    "cascadeTestingOffered": "Yes",
    "variantReclassificationPolicy": true,
    "minimumAge": 18,
    "uniqueFeatures": "Focus on accessibility and user experience; 30-gene panel covers most actionable risks; strong employer/enterprise market presence",
    "limitations": "Smaller panel than Myriad/Invitae; TAT is slower (3-5 weeks)",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-6",
    "name": "Comprehensive Hereditary Cancer Panel",
    "vendor": "Quest Diagnostics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood",
    "sampleType": "Whole blood",
    "sampleVolume": "5 mL",
    "method": "NGS with Deletion/Duplication",
    "methodCitations": "https://testdirectory.questdiagnostics.com/test/test-detail/38600/",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 66,
    "genesAnalyzedCitations": "https://testdirectory.questdiagnostics.com/test/test-detail/38600/",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "APC",
      "MUTYH",
      "TP53",
      "PTEN",
      "STK11",
      "CDH1"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "Cowden",
      "FAP"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Colorectal",
      "Endometrial",
      "Pancreatic",
      "Prostate",
      "Gastric"
    ],
    "analyticalSensitivity": 99,
    "analyticalSpecificity": 99,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified, CAP Accredited",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Insurance/Medicare",
    "financialAssistance": "Quest Financial Assistance",
    "cptCodes": "81432, 81433",
    "tat": "14-21 days",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Variant classification"
    ],
    "geneticCounselingIncluded": "Optional - through partners",
    "cascadeTestingOffered": "No - standard ordering required",
    "variantReclassificationPolicy": true,
    "uniqueFeatures": "Broad access via Quest patient service centers nationwide",
    "limitations": "Less specialized than dedicated genetic labs (Myriad/Ambry)",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-7",
    "name": "VistaSeq Hereditary Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood or saliva",
    "sampleVolume": "10 mL blood",
    "method": "NGS with Deletion/Duplication",
    "methodCitations": "https://womenshealth.labcorp.com/providers/hereditary-cancer/vistaseq",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 27,
    "genesAnalyzedCitations": "https://womenshealth.labcorp.com/providers/hereditary-cancer/vistaseq",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "EPCAM",
      "APC",
      "MUTYH",
      "TP53",
      "PTEN"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "FAP",
      "Cowden"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Colorectal",
      "Pancreatic",
      "Prostate"
    ],
    "analyticalSensitivity": 99,
    "analyticalSpecificity": 99,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Insurance/Medicare",
    "financialAssistance": "Labcorp Patient Assistance",
    "cptCodes": "81432, 81433",
    "tat": "21-28 days",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Variant classification"
    ],
    "geneticCounselingIncluded": "Optional - Integrated Genetics counselors available",
    "cascadeTestingOffered": "Yes - mutation-specific testing available",
    "variantReclassificationPolicy": true,
    "uniqueFeatures": "Integrated with Labcorp's massive distribution network; focused on high-penetrance actionable genes",
    "limitations": "27-gene panel is smaller than 'Comprehensive' panels from competitors; tighter focus on most actionable genes",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-8",
    "name": "xG / xG+ Hereditary Cancer",
    "vendor": "Tempus",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood or saliva",
    "sampleVolume": "4 mL",
    "method": "NGS with Deletion/Duplication",
    "methodCitations": "https://www.tempus.com/oncology/genetic-testing/hereditary-cancer/",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 52,
    "genesAnalyzedNotes": "xG = 52 genes; xG+ = 88 genes",
    "genesAnalyzedCitations": "https://www.tempus.com/oncology/genetic-testing/hereditary-cancer/",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "PALB2",
      "ATM",
      "CHEK2"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Colorectal",
      "Pancreatic",
      "Prostate",
      "Endometrial"
    ],
    "analyticalSensitivity": 99,
    "analyticalSpecificity": 99.9,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Insurance/Medicare",
    "selfPayPrice": 250,
    "financialAssistance": "Tempus Financial Assistance",
    "tat": "2 weeks",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Variant classification",
      "Clinical Guidelines"
    ],
    "geneticCounselingIncluded": "Optional",
    "cascadeTestingOffered": "Yes",
    "variantReclassificationPolicy": true,
    "uniqueFeatures": "Seamlessly integrates with xT tumor profiling; germline analysis performed by partner lab (GeneDx); allows oncologists to order both tumor and hereditary tests together",
    "limitations": "Germline testing outsourced to GeneDx",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-9",
    "name": "Comprehensive Common Cancer Panel",
    "vendor": "GeneDx",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood or saliva",
    "sampleVolume": "2-5 mL",
    "method": "NGS with Deletion/Duplication",
    "methodCitations": "https://providers.genedx.com/Resources/TIS-Files/TIS-B275.pdf",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 49,
    "genesAnalyzedCitations": "https://providers.genedx.com/Resources/TIS-Files/TIS-B275.pdf",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "APC",
      "MUTYH",
      "TP53",
      "PTEN"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "FAP",
      "Cowden",
      "Peutz-Jeghers"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Colorectal",
      "Pancreatic",
      "Prostate",
      "Uterine",
      "Melanoma"
    ],
    "analyticalSensitivity": 99,
    "analyticalSpecificity": 99.9,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified, CAP Accredited",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Insurance/Medicare",
    "financialAssistance": "Financial Assistance Program",
    "cptCodes": "81432, 81433",
    "tat": "14-21 days",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Variant classification",
      "Management guidelines"
    ],
    "geneticCounselingIncluded": "Optional",
    "cascadeTestingOffered": "Yes",
    "variantReclassificationPolicy": true,
    "pediatricTesting": true,
    "uniqueFeatures": "Expertise in rare diseases; often handles complex cases; powers Tempus xG germline testing",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-10",
    "name": "Full Comprehensive Cancer Panel",
    "vendor": "Fulgent Genetics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "Whole blood or saliva",
    "sampleVolume": "4 mL blood",
    "method": "NGS with Deletion/Duplication",
    "methodCitations": "https://www.fulgentgenetics.com/comprehensivecancer-full",
    "sequencingPlatform": "Illumina",
    "genesAnalyzed": 154,
    "genesAnalyzedCitations": "https://www.fulgentgenetics.com/comprehensivecancer-full",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2",
      "EPCAM",
      "APC",
      "TP53",
      "PTEN",
      "PALB2",
      "ATM",
      "CHEK2"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "Cowden",
      "FAP",
      "All major syndromes"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Ovarian",
      "Colorectal",
      "Endometrial",
      "Pancreatic",
      "Prostate",
      "Gastric",
      "Renal",
      "Thyroid",
      "Brain",
      "Sarcoma",
      "Hematologic"
    ],
    "analyticalSensitivity": 99.9,
    "analyticalSensitivityNotes": ">99% at 50x coverage",
    "analyticalSpecificity": 99.9,
    "deletionDuplicationAnalysis": "Yes",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "CLIA Certified, CAP Accredited",
    "nyApproved": true,
    "reimbursement": "Broad Coverage",
    "reimbursementNotes": "Insurance/Medicare",
    "financialAssistance": "Financial Assistance Available",
    "cptCodes": "81432, 81433",
    "tat": "2-3 weeks",
    "availableRegions": [
      "US",
      "International"
    ],
    "reportIncludes": [
      "Variant classification"
    ],
    "geneticCounselingIncluded": "Optional",
    "cascadeTestingOffered": "Yes - single gene testing for relatives",
    "variantReclassificationPolicy": true,
    "pediatricTesting": true,
    "uniqueFeatures": "Largest panel available (154 genes); offers pediatric-specific panels; appeals to specialists wanting comprehensive coverage",
    "limitations": "Large gene lists increase VUS rate",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-08: Added via OpenOnco HCT category launch"
  },
  {
    "id": "hct-11",
    "name": "Invitae Hereditary Breast Cancer Panel",
    "vendor": "Invitae",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "genesAnalyzed": 18,
    "genesAnalyzedCitations": "https://www.invitae.com/providers/test-catalog/test-01202",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "PALB2",
      "TP53",
      "PTEN",
      "CDH1",
      "ATM",
      "CHEK2"
    ],
    "syndromesDetected": [
      "HBOC",
      "Li-Fraumeni",
      "Cowden",
      "Hereditary Diffuse Gastric Cancer"
    ],
    "fdaStatus": "CLIA LDT",
    "nyApproved": "Varies by test / state rules",
    "tat": "Varies by order",
    "tatCitations": "https://www.invitae.com/providers/test-catalog/test-01202",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-12",
    "name": "Invitae Hereditary Breast Cancer Guidelines-Based Panel",
    "vendor": "Invitae",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "genesAnalyzed": 13,
    "genesAnalyzedCitations": "https://www.invitae.com/providers/test-catalog/test-01206",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "TP53",
      "PTEN",
      "STK11",
      "PALB2",
      "CDH1",
      "ATM",
      "CHEK2"
    ],
    "syndromesDetected": [
      "HBOC",
      "Li-Fraumeni",
      "Cowden",
      "Peutz-Jeghers",
      "Hereditary Diffuse Gastric Cancer"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-13",
    "name": "Invitae BRCA1 and BRCA2 STAT Panel",
    "vendor": "Invitae",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "sampleType": "3 mL whole blood in purple-top EDTA tube; alternate: saliva",
    "genesAnalyzed": 2,
    "genesAnalyzedCitations": "https://www.invitae.com/providers/test-catalog/test-50002",
    "keyGenes": [
      "BRCA1",
      "BRCA2"
    ],
    "syndromesDetected": [
      "HBOC"
    ],
    "fdaStatus": "CLIA LDT",
    "nyApproved": true,
    "tat": "5â€“12 calendar days (7 days on average)",
    "tatCitations": "https://www.invitae.com/providers/test-catalog/test-50002",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-14",
    "name": "Invitae Hereditary Thyroid Cancer Panel",
    "vendor": "Invitae",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "genesAnalyzed": 8,
    "genesAnalyzedCitations": "https://www.invitae.com/providers/test-catalog/test-01301",
    "keyGenes": [
      "RET",
      "PTEN",
      "APC",
      "DICER1",
      "PRKAR1A",
      "SDHB",
      "SDHD",
      "TP53"
    ],
    "cancerTypesAssessed": [
      "Thyroid"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-15",
    "name": "Invitae Hereditary Pancreatic Cancer Panel",
    "vendor": "Invitae",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "NGS germline multi-gene panel",
    "methodCitations": "https://www.invitae.com/providers/test-catalog/test-01261",
    "cancerTypesAssessed": [
      "Pancreatic"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-16",
    "name": "VistaSeq Hereditary Breast Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Breast"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-17",
    "name": "VistaSeq Hereditary Colorectal Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Colorectal"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-18",
    "name": "VistaSeq Hereditary Ovarian Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Ovarian"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-19",
    "name": "VistaSeq Hereditary Endometrial Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Endometrial"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-20",
    "name": "VistaSeq Hereditary Gastric Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Gastric"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-21",
    "name": "VistaSeq Hereditary Pancreatic Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Pancreatic"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-22",
    "name": "VistaSeq Hereditary Prostate Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Prostate"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-23",
    "name": "VistaSeq Hereditary Melanoma Cancer Panel",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline hereditary cancer focused subpanel",
    "methodCitations": "https://oncology.labcorp.com/vistaseq-hereditary-cancer",
    "cancerTypesAssessed": [
      "Melanoma"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-24",
    "name": "BRCAssure: BRCA1 Targeted Analysis",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "genesAnalyzed": 1,
    "genesAnalyzedCitations": "https://oncology.labcorp.com/assets-media/2277",
    "keyGenes": [
      "BRCA1"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-25",
    "name": "BRCAssure: BRCA2 Targeted Analysis",
    "vendor": "Labcorp",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "genesAnalyzed": 1,
    "genesAnalyzedCitations": "https://oncology.labcorp.com/assets-media/2277",
    "keyGenes": [
      "BRCA2"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-26",
    "name": "Full Comprehensive Cancer Panel (Pan-Cancer)",
    "vendor": "Fulgent Genetics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood",
    "method": "Germline hereditary cancer testing; comprehensive panel",
    "methodCitations": "https://www.fulgentgenetics.com/products/oncology/hereditarycancer.html",
    "genesAnalyzed": 154,
    "genesAnalyzedCitations": "https://fulgentgenetics.com/content/flyer/FLY-Hereditary_Cancer-2024-V1.pdf",
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-27",
    "name": "Gastric Cancer Panel",
    "vendor": "PreventionGenetics (Exact Sciences)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "NGS with CNV (PGselect Platform)",
    "methodCitations": "https://www.preventiongenetics.com/tests/gastric-cancer-panel",
    "genesAnalyzed": 19,
    "genesAnalyzedCitations": "https://www.preventiongenetics.com/tests/gastric-cancer-panel",
    "cancerTypesAssessed": [
      "Gastric"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-28",
    "name": "PTEN Hamartoma Tumor Syndrome via the PTEN Gene",
    "vendor": "PreventionGenetics (Exact Sciences)",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "genesAnalyzed": 1,
    "genesAnalyzedCitations": "https://www.preventiongenetics.com/tests/pten-hamartoma-tumor-syndrome-via-the-pten-gene",
    "keyGenes": [
      "PTEN"
    ],
    "syndromesDetected": [
      "Cowden Syndrome / PTEN Hamartoma Tumor Syndrome"
    ],
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-29",
    "name": "FoundationOne Germline",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Germline testing",
    "methodCitations": "https://www.foundationmedicine.com/test/germline-testing",
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-30",
    "name": "FoundationOne Germline More",
    "vendor": "Foundation Medicine",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "method": "Expanded germline testing offering",
    "methodCitations": "https://www.foundationmedicine.com/test/germline-testing",
    "fdaStatus": "CLIA LDT",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-31",
    "name": "BRACAnalysis CDx",
    "vendor": "Myriad Genetics",
    "productType": "Central Lab Service",
    "sampleCategory": "Blood or Saliva",
    "genesAnalyzed": 2,
    "genesAnalyzedCitations": "https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140020b.pdf",
    "keyGenes": [
      "BRCA1",
      "BRCA2"
    ],
    "fdaStatus": "FDA Approved (PMA)",
    "fdaStatusNotes": "FDA-approved companion diagnostic for PARP inhibitors",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-32",
    "name": "23andMe Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants)",
    "vendor": "23andMe",
    "productType": "Direct-to-Consumer",
    "sampleCategory": "Saliva",
    "genesAnalyzed": 2,
    "genesAnalyzedCitations": "https://www.23andme.com/en-int/company-stories/fda-authorizes-first-direct-to-consumer-test-for-breast-cancer-risk/",
    "keyGenes": [
      "BRCA1",
      "BRCA2"
    ],
    "fdaStatus": "DTC FDA Authorized",
    "fdaStatusNotes": "Limited to 3 Ashkenazi Jewish founder mutations; not comprehensive BRCA sequencing",
    "limitations": "Tests only 3 specific variants common in Ashkenazi Jewish population; negative result does not rule out BRCA mutations",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-09: Initial entry from batch submission"
  },
  {
    "id": "hct-33",
    "name": "AbsoluteDx",
    "vendor": "Allelica",
    "productType": "Central Lab Service",
    "sampleCategory": "Saliva",
    "sampleType": "Saliva (non-invasive collection kit)",
    "method": "Clinical exome sequencing (NCCN v1.2026 + ACMG Secondary Findings v3.3 genes) combined with multi-ancestry polygenic risk scores (PRS); integrates monogenic and polygenic risk to provide absolute risk assessment",
    "methodCitations": "https://allelica.com/absolutedx",
    "sequencingPlatform": "Illumina (Clinical Exome)",
    "keyGenes": [
      "BRCA1",
      "BRCA2",
      "PALB2",
      "ATM",
      "CHEK2",
      "TP53",
      "MLH1",
      "MSH2",
      "MSH6",
      "PMS2"
    ],
    "syndromesDetected": [
      "HBOC",
      "Lynch Syndrome",
      "Li-Fraumeni",
      "Cowden"
    ],
    "cancerTypesAssessed": [
      "Breast",
      "Prostate",
      "Colorectal",
      "Ovarian",
      "Pancreatic"
    ],
    "deletionDuplicationAnalysis": "Yes",
    "prsIncluded": true,
    "prsNotes": "Multi-ancestry polygenic risk scores modulate penetrance of monogenic variants; ~50% of CHEK2 carriers fall above/below guideline thresholds when PRS factored in. PRS identifies ~20% of breast cancer cases where high genetic risk caused disease beyond BRCA1/2/ATM/CHEK2/PALB2.",
    "prsCitations": "Nature Communications (multi-ancestry PRS validation); Baylor College of Medicine collaboration",
    "fdaStatus": "CLIA LDT",
    "fdaStatusNotes": "Launched October 2025",
    "reimbursement": "Coverage Varies",
    "reimbursementNotes": "Emerging coverage; check with vendor",
    "availableRegions": [
      "US"
    ],
    "reportIncludes": [
      "Monogenic variant classification",
      "Polygenic risk score",
      "Absolute risk calculation",
      "Management recommendations"
    ],
    "geneticCounselingIncluded": "Check with vendor",
    "uniqueFeatures": "First test integrating PRS to modulate penetrance of monogenic variants; provides absolute risk not just variant detection; multi-ancestry validated PRS. Note: Allelica also offers non-cancer tests (cardiovascular, metabolic, neurological) through AbsoluteDx platform - only cancer capabilities listed here.",
    "limitations": "PRS utility varies by ancestry; newer platform with less published validation than established competitors",
    "numPublications": 1,
    "numPublicationsPlus": true,
    "numPublicationsNotes": "Nature Communications (multi-ancestry PRS); ASHG 2024 presentations",
    "vendorVerified": false,
    "vendorRequestedChanges": "2026-01-11: Added via vendor submission from Giordano Botta (CEO, Allelica). Cancer-focused subset of multi-disease AbsoluteDx platform."
  }
]